<DOC>
	<DOCNO>NCT00566852</DOCNO>
	<brief_summary>RATIONALE : Memantine may able decrease side effect cause whole-brain radiation therapy . It yet know memantine effective preventing side effect cause whole-brain radiation therapy . PURPOSE : This randomized phase III trial study memantine see well work compare placebo prevent side effect cause whole-brain radiation therapy patient brain metastasis solid tumor .</brief_summary>
	<brief_title>Memantine Preventing Side Effects Patients Undergoing Whole-Brain Radiation Therapy Brain Metastases From Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine whether addition memantine hydrochloride whole-brain radiotherapy ( WBRT ) preserve cognitive function , specifically memory , measure Hopkins Verbal Learning Test delay recall ( HVLT-delayed recall ) , placebo WBRT patient brain metastases 24 week start drug treatment . Secondary - Determine whether addition memantine hydrochloride preserve cognitive function , specifically memory , measure HVLT-delayed recall 8 week , 16 week , 12 month start drug treatment . - Determine whether addition memantine hydrochloride increase time neurocognitive failure measure cognitive decline battery test include HVLT free recall , delay recall , delayed recognition ; Controlled Word Association Test ( COWAT ) ; Trail Making Test Parts A B ( TMT ) ; Medical Outcomes Scale-Cognitive Functioning Subscale ( MOS ) ; Mini-Mental Status Examination ( MMSE ) . - Evaluate potential benefit memantine hydrochloride change overall quality life , measure Functional Assessment Cancer Therapy-Brain ( FACT-Br ) subscale . - Determine whether addition memantine hydrochloride increase progression-free survival . - Determine whether addition memantine hydrochloride increase overall survival . - Compare adverse event treatment arm accord CTCAE v3.0 criterion . - Collect serum , plasma , buffy coat cell , urine , CSF future translational research analysis . OUTLINE : This multicenter study . Patients stratify accord recursive partitioning analysis ( RPA ) prognostic class ( class I vs class II control systemic disease ) prior surgical therapy ( none v radiosurgery surgical resection ) . Patients randomize 1 2 treatment arm . - Arm I : Patients undergo whole-brain radiotherapy ( WBRT ) 5 day week 3 week ( 15 fraction ) . Patients also receive oral memantine hydrochloride daily begin day 1 WBRT continue 24 week . - Arm II : Patients undergo WBRT arm I . Patients also receive oral placebo daily begin day 1 WBRT continue 24 week . After completion study treatment , patient follow 6 month , every 4 month 1 year , every 6 month 2 year , annually thereafter .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm diagnosis solid tumor malignancy within past 5 year If original histologic proof malignancy &gt; 5 year , pathological ( i.e. , recent ) confirmation require ( e.g. , systemic metastasis brain metastasis ) Brain metastasis must visible contrastenhanced MRI contrast enhance CT scan ( patient unable undergo MRI within past 28 day ) Patients unable undergo MRI image noncompatible device eligible , provide contrastenhanced CT scan obtain sufficient quality Patients undergone radiosurgery surgical resection planning adjuvant wholebrain radiotherapy visible disease need baseline MRI Must stable systemic disease ( i.e . evidence systemic disease progression within past 3 month ) Patients brain metastasis initial presentation eligible need demonstrate 3 month stable scan PATIENT CHARACTERISTICS : Inclusion Karnofsky performance status 70100 % Serum creatinine ≤ 3 mg/dL creatinine clearance ≥ 30 mL/min Total bilirubin ≤ 2.5 mg/dL BUN &lt; 20 mg/dL Minimental status exam score ≥ 18 Negative serum pregnancy test Fertile patient must practice adequate contraception Exclusion Severe , active comorbidity , define follow : Unstable angina and/or congestive heart failure require hospitalization within last 6 month Transmural myocardial infarction within last 6 month Acute bacterial fungal infection require intravenous antibiotic time registration Chronic obstructive pulmonary disease exacerbation respiratory illness require hospitalization preclude study therapy time registration Hepatic insufficiency result clinical jaundice and/or coagulation defect Pregnant lactate woman Prior allergic reaction memantine hydrochloride Current alcohol drug abuse Intractable seizure adequate anticonvulsant therapy ( i.e. , one seizure per month past 2 month ) PRIOR CONCURRENT THERAPY : Inclusion At least 14 day 56 day since prior therapy brain metastasis , include radiosurgery surgical resection No systemic chemotherapy 14 day prior , , 14 day completion wholebrain radiotherapy ( WBRT ) Exclusion Prior cranial radiotherapy Patients may receive 3 prior WBRT treatment still register randomized protocol provide WBRT parameter meet protocol requirement Chronic shortacting benzodiazepine use</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>cognitive/functional effect</keyword>
	<keyword>neurotoxicity</keyword>
	<keyword>tumor metastatic brain</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>